Additionally, based on the preclinical evidence that supports the presence of an immunogenic microenvironment in SMARCB1-defective tumors [94], a dedicated phase II clinical trial evaluating the efficacy of nivolumab and ipilimumab SMARCB1-negative pediatric cancers has been launched (NCT04416568). This evidence concerns the gene SMARCB1 and cancer.